Qasim, W. (2022). Genome edited allogeneic donor 'universal' chimeric antigen receptor T Cells. Blood, blood.2022016204. doi:10.1182/blood.2022016204

Ottaviano, G., & Qasim, W. (2022). Genome-Edited T Cell Therapies. Hematology / Oncology Clinics of North America. doi:10.1016/j.hoc.2022.03.006

Cooper, M. L., Ottaviano, G., DiPersio, J. F., & Qasim, W. (2022). Off-the-Shelf CAR-T. Cancer Drug Discovery and Development (pp. 109-120). doi:10.1007/978-3-030-87849-8_7

Ottaviano, G., Georgiadis, C., Gkazi, S. A., Syed, F., Zhan, H., Etuk, A., . . . TT52 CRISPR-CAR group. (2022). Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Science Translational Medicine, 14 (668), eabq3010. doi:10.1126/scitranslmed.abq3010

Rota, I., Handel, A., Klein, F., Maio, S., Dhalla, F., Deadman, M., . . . Holländer, G. (2021). A FOXN1 mutation competitively displaces wild-type FOXN1 from higher-order nuclear condensates to cause immunodeficiency. doi:10.1101/2021.03.28.437237

Georgiadis, C., Rasaiyaah, J., Gkazi, S. A., Preece, R., Etuk, A., Christi, A., & Qasim, W. (2021). Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia. doi:10.1038/s41375-021-01282-6

Jayarajan, V., Kounatidou, E., Qasim, W., & Di, W. -. L. (2021). Ex-vivo gene modification therapy for genetic skin diseases - recent advances in gene modification technologies and delivery. Exp Dermatol. doi:10.1111/exd.14314

Rota, I. A., Handel, A. E., Maio, S., Klein, F., Dhalla, F., Deadman, M. E., . . . Holländer, G. A. (2021). FOXN1 forms higher-order nuclear condensates displaced by mutations causing immunodeficiency. Science Advances, 7 (49), eabj9247. doi:10.1126/sciadv.abj9247

Qasim, W. (2021). Genome editing of therapeutic T cells. Gene and Genome Editing, 2, None-?. doi:10.1016/j.ggedit.2021.100010

Roddie, C., O'Reilly, M. A., Marzolini, M. A. V., Wood, L., Dias, J., Garai, A. C., . . . Peggs, K. S. (2020). ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies. Presented at: 62nd Annual Meeting of the American-Society-of-Hematology (ASH). doi:10.1182/blood-2020-137768